Q-omics provides the consensus-scored ZNF230 profile across patient tissues and cancer cell-line models. ZNF230 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF230 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF230 RNA expression shows 20,020 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF230 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF230 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF230 survival associations across molecular data types. ZNF230 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF230 RNA expression–survival associations across cancer types. High ZNF230 expression shows unfavorable associations in LGG, UVM and LUSC, but favorable associations in KIRC, PAAD and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF230 RNA expression.
This table summarizes ZNF230 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF230. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF230 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, KIRC, LIHC and CHOL. The THCA box plot shows higher ZNF230 RNA expression in normal versus tumor tissue (log2 FC = −0.721, t-test p < 0.001).
This table shows molecular features associated with ZNF230 in patient tissues and cancer cell lines. In patient samples, ZNF230 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF230 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
